Immuneering Advances Phase 3 and Readies ASCO Data

What happened

Immuneering reported Q1 2026 results, highlighting that its pivotal Phase 3 MAPKeeper 301 trial for atebimetinib in first-line pancreatic cancer is now recruiting (NCT07562152), with first patient dosing on track for mid-2026. The company also announced that new survival data from 55 first-line patients will be presented as an oral presentation at the 2026 ASCO Annual Meeting on June 1. Additionally, a third-line patient on atebimetinib monotherapy has achieved 27 months progression-free survival with ongoing 85% tumor reduction. The company ended Q1 with $198.6M in cash, providing runway into 2029.

Implication

The operational progress on MAPKeeper 301 and the upcoming ASCO data reduce near-term uncertainty. Yet, the pivotal test is whether the expanded survival dataset sustains the 64% 12-month OS signal seen earlier. Bull case requires convincing durability beyond 12 months and clear Phase 3 execution. Cash runway into 2029 limits dilution risk, supporting a base case of $6.50. Monitor ASCO data on June 1 for confirmation or disappointment.

Thesis delta

The prior report flagged MAPKeeper 301's lack of ClinicalTrials.gov visibility as a key risk; this is now resolved with the trial recruiting and an NCT number assigned. Additionally, the expanded survival data coming at ASCO increases the probability of near-term catalyst. However, the bear case remains that the data may not meet elevated expectations, and the mid-2026 FPI timeline must still be executed.